A Novel Ruthenium(II) Complex and its Synergistic Anti-Leukemia Activity with GidA Protein via Dual-Pathway Apoptosis
Drug Research · 2026-07-27
DOI: 10.1055/a-2905-1945 ↗Abstract
AbstractThis study demonstrates the effective anticancer activity of a semi-synthetic complex integrating the GidA protein and the ruthenium(II) complex against K562 human leukemia cells. Monotherapy evaluation revealed exceptional cytotoxicity, with half-maximal inhibitory concentration values of 0.058 μg/mL for GidA (a novel topoisomerase II inhibitor) and 14.1 μg/mL for Ru(II). Subsequently, isobologram analysis of six combination ratios identified profound synergy in formulations with elevated Ru(II) concentrations (combinations 4 and 5; sum of the fractional inhibitory concentration=0.17–0.86). All these synergistic complexes induced up to 73.91% apoptosis, exceeding single-agent efficacy (p
EUVIMED